{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002270","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.279450+00:00","generated_at":"2026-06-03T07:01:54.912112+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nasdaq confirms Aptose regained compliance with Listing Rule 5635(d) after warrant amendment","bullets":["Aptose and Hanmi amended warrant to cap exercise at 19.99% of outstanding shares without shareholder approval.","Hanmi received 2,339,181 warrants at $1.71/share, exercisable for 5 years from issuance.","Nasdaq Staff determined compliance with Rule 5635(d) regained; matter closed.","Original violation stemmed from Jan 25, 2024 Hanmi transaction that issued >20% shares at a discount."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002270","json":"https://secwatch.observer/filing/0001171843-24-002270.json","markdown":"https://secwatch.observer/filing/0001171843-24-002270.md","text":"https://secwatch.observer/filing/0001171843-24-002270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002270/0001171843-24-002270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002270/f8k_042624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:01:54.912112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cfcd98a30d40cd283767d3a6eb3f57bb8bb116c","claim":"Aptose Biosciences Inc. amended Amended and Restated Warrant to Purchase Common Shares with Hanmi Pharmaceutical Co., Ltd. valued at 2,339,181 warrants at $1.71 per share (effective 2024-04-24).","evidence_excerpt":"On April 24, 2024, Aptose Biosciences Inc. (the “ Company ”) entered into an Amended and Restated Warrant to Purchase Common Shares (the “ Amended Warrant Agreement ”) with Hanmi Pharmaceutical Co., Ltd. (“ Hanmi ”) in order to comply with Listing Rule 5635 of The Nasdaq Stock Market LLC (“ Nasdaq ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002270/0001171843-24-002270-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Hanmi Pharmaceutical Co., Ltd."},{"label":"Value","value":"2,339,181 warrants at $1.71 per share"},{"label":"Effective","value":"2024-04-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}